Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-3373 (AbbVie Inc.)
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous (studied In Healthy Volunteers)
01
Overview
ABBV-3373 is an investigational antibody-drug conjugate (ADC) developed by AbbVie for the treatment of rheumatoid arthritis and other immune-mediated inflammatory diseases. It consists of the anti-tumor necrosis factor (anti-TNF) monoclonal antibody adalimumab covalently linked to a proprietary small-molecule glucocorticoid receptor modulator (GRM). The design aims to deliver the glucocorticoid payload directly into activated immune cells expressing membrane-bound TNF, thereby precisely targeting inflammation while minimizing systemic side effects typically associated with glucocorticoids. Clinical studies have shown that ABBV-3373 can reduce disease activity in rheumatoid arthritis patients more effectively than historical data for adalimumab alone, with a safety profile generally similar to adalimumab[1][2][3][7].
- Other names
- glucocorticoid receptor modulator linked to adalimumab
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ABBV-3373 (AbbVie Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-3373 (AbbVie Inc.).